openPR Logo
Press release

Deadline on Feb. 8th coming up in Lawsuit for INvestros in Revance Therapeutics, Inc. (NASDAQ: RVNC)

02-01-2022 04:30 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on February 8, 2022 in the lawsuit for certain investors in Revance Therapeutics, Inc. (NASDAQ: RVNC).

A Deadline is coming up on February 8, 2022 in the lawsuit for certain investors in Revance Therapeutics, Inc. (NASDAQ: RVNC).

A deadline is coming up on February 8, 2022 in the lawsuit filed for certain investors of Revance Therapeutics, Inc. (NASDAQ: RVNC) over alleged securities laws violations by Revance Therapeutics, Inc.

Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and there are strict and short deadlines running. Deadline: February 8, 2022. NASDAQ: RVNC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Revance Therapeutics, Inc. (NASDAQ: RVNC) common shares between November 25, 2019 and October 11, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 25, 2019 and October 11, 2021, the Defendants made false and/or misleading statements and/or failed to disclose that quality control deficiencies existed at the Company’s manufacturing facility for DAXI, that the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form, that accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on Feb. 8th coming up in Lawsuit for INvestros in Revance Therapeutics, Inc. (NASDAQ: RVNC) here

News-ID: 2542576 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Revance

Botulinum Toxin Injections Market Is Booming Worldwide | Allergan, Ipsen, Revanc …
HTF MI just released the Global Botulinum Toxin Injections Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2033. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach. Major Giants in Botulinum Toxin Injections Market are: Allergan (US), Ipsen
Aesthetic Service Market Is Booming Worldwide | Allergan, Galderma, Merz Pharmac …
The Global Aesthetic Service Market is estimated to be valued at USD 21.94 Bn in 2025 and is expected to reach USD 36.40 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 7.5% from 2025 to 2032. The qualitative latest Research report (2025-2032) on the Aesthetic Service Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes
Lip Augmentation Market Trends and Forecast | Key Players: Revance Therapeutics, …
Lip Augmentation Market Overview The global lip augmentation market is projected to grow from USD 3.1 billion in 2024 to USD 6.1 billion by 2033, exhibiting a CAGR of 7.78% during the forecast period. Coherent Market Insights is pleased to release its latest Lip Augmentation Market research report, offering an in-depth analysis of the U.S. Lip Augmentation Market Landscape from 2025 to 2032. This report delivers reliable projections across national and regional
Facial Injectable Market Is Booming So Rapidly | Evolus, Hugel, Revance
The Global Facial Injectable Market Size is estimated at $12.9 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.1% to reach $30.7 Billion by 2034. The latest study released on the Global Facial Injectable Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Facial Injectable market study covers significant research data and proofs to be a handy resource document for
Investigation announced for Investors in Revance Therapeutics, Inc. (NASDAQ: RVN …
An investigation was announced for long-term investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) concerning potential breaches of fiduciary duties by certain directors and officers of Revance Therapeutics, Inc. Investors who are current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVN …
An investor in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) filed a lawsuit over alleged Securities Laws violations by Revance Therapeutics, Inc. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and for certain investors are short and strict deadlines running. Deadline: February 8, 2022. NASDAQ: RVNC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Newark, CA based Revance Therapeutics, Inc.,